Back to search
FDAFDA · Food and drugs·Recall number D-1166-2022

Tegsedi (inotersen) Injection 284 mg/1.5 mL, Rx Only, Sterile solution for Subcutaneous Use, 4 prefilled syringes, each containing 284 mg of inotersen, (equivalent to 300 mg inotersen sodium in 1.5 ml of solution), Distributed by Sobi, Inc. Inc Waltham MA 02451, NDC: 72126-007-01

Published July 6, 2022 · Recall initiated: May 23, 2022

Summary

FDA records drug Class I recall D-1166-2022, published July 6, 2022 and initiated May 23, 2022. Recalling firm: Akcea Therapeutics, Inc.; Status: Terminated; Reported quantity: 450 cartons; Lot: Lots: 028C21AB, 028C21AC, Exp. 05/2025. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Superpotent: High Out of specification (OOS) test result for percent label claim (%LC).

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Akcea Therapeutics, Inc.
Distributor
KY, USA
Lot
Lots: 028C21AB, 028C21AC, Exp. 05/2025
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Tegsedi (inotersen) Injection 284 mg/1.5 mL, Rx Only, Sterile solution for Subcutaneous Use, 4 prefilled syringes, each containing 284 mg of inotersen, (equivalent to 300 mg inotersen sodium in 1.5 ml of solution), Distributed by Sobi, Inc. Inc Waltham MA 02451, NDC: 72126-007-01 recalled?

Yes. FDA published recall D-1166-2022 on July 6, 2022. Reported hazard: Superpotent: High Out of specification (OOS) test result for percent label claim (%LC).

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail